First Line Single-Agent Ruxolitinib For Grade Ii-Iii Acute Graft-Versus-Host Disease In Patients With Severe Infectious Complications: Case Series
BONE MARROW TRANSPLANTATION（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined